Search | Clinical Trials Finder

Conditions: Cardiovascular Risk Factor
Interventions: No to Low Endogenous Estrogen, Estradiol; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Headache, Occipital Nerve Block
Interventions: Bupivacaine, Lidocaine, Dexamethasone, Normal saline, Greater/lesser occipital nerve blocks; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Surgical Wound Infections
Interventions: Vancomycin, Placebo (Saline Solution); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions: Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Intracranial Atherosclerosis
Interventions: Feraheme; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HPV
Interventions: Gardasil-9, Lidocaine injection, Lorazepam; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions: ONCOS-102, Durvalumab, Cyclophosphamide; Biological · Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: San Diego, California • Miami, Florida • Buffalo, New York + 3 more

Conditions: Dental Pain
Interventions: Bupivacaine liposome, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Plantar Fasciitis
Interventions: Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension; Procedure
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Chronic Pain
Interventions: Oxytocin, Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Melanoma
Interventions: CP 870,893, Peptides, Oncovir poly IC:LC; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
Interventions: Y-3 for injection, Placebo; Drug
Lead sponsor: Neurodawn Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Webster, Texas

Conditions: Urinary Incontinence, Stress, Urinary Incontinence, Urge
Interventions: Botox® injection, Mid-urethral sling; Drug · Device
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more

Conditions: Coronary Artery Disease, Atrial Fibrillation
Interventions: Liposomal bupivacaine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions: Lumason, Sonazoid; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Prostate Cancer
Interventions: 18F-DCFPyL Injection, 18F-NaF; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoarthritis
Interventions: Bupivacaine, Morphine, Methylprednisolone, Cefazolin, Normal saline, Midazolam, Propofol, Dexamethasone, 8 MHz. Chiba needle, 22 G / 4 inches; Drug · Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Failure, Perimenopausal Disorder, Hormone Disturbance
Interventions: lipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection, emulsification tSVF; Procedure · Device · Drug
Lead sponsor: Black Tie Medical, Inc.; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Colchester, Vermont

Conditions: Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
Interventions: Biological/Vaccine: Bacillus Calmette-Guerin (BCG); Biological
Lead sponsor: Steven E Arnold, MD; Other
Eligibility: 55 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Post-operative Pain
Interventions: 15mL 0.25% bupivacaine, Genicular nerve block, Saline; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Interventions: Efprezimod alfa, Methotrexate, Tacrolimus, Placebo; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Acute Pain, Surgery, Regional Anesthesia
Interventions: Epidural, TAP Block; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions: Reltecimod 0.5 mg/kg, Placebo; Drug
Lead sponsor: Atox Bio Ltd; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Search by objective public record fields.

Menopause Effects on Vascular Function

Steroids in Occipital Nerve Block for Treatment of Headache

Prevention of Neurosurgical Wound Infections

Platelet Rich Plasma Injections In Young And Old Human Subjects

Predicting Stroke Risk in ICAD With Novel MRI

HPV Vaccine Reduced Dose

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis

Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

A Phase 1 Study of Y-3 in US Healthy Volunteers.

Sling vs Botox for Mixed Incontinence

A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

Y-90 Treatment Response Using Transarterial Radioembolization

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.

The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)

Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF

A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD

Genicular Nerve Block for Total Knee Arthroplasty

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Comparison of Epidural and TAP Block in Abdominal Surgery

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER